Evogene Ltd. :EVGN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016

Evogene Ltd. reports financial results for the quarter ended September 30, 2016.

We analyze the earnings along side the following peers of Evogene Ltd. – E. I. du Pont de Nemours and Company, 22nd Century Group, Inc., Monsanto Company, Compugen Ltd. and Dow Chemical Company (DD-US, XXII-US, MON-US, CGEN-US and DOW-US) that have also reported for this period.


  • Summary numbers: Revenues of USD 1.54 million, Net Earnings of USD -5.11 million.
  • Gross margins narrowed from 24.84% to 7.68% compared to the same period last year, operating (EBITDA) margins now -298.50% from -96.68%.
  • Year-on-year change in operating cash flow of -20% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30
Relevant Numbers (Quarterly)
Revenues (mil) 1.54 1.81 2.02 2.46 3.31
Revenue Growth (%YOY) -53.58 -31.93 -25.36 -32.34 4.58
Earnings (mil) -5.11 -4.46 -3.37 -5.47 -3.38
Earnings Growth (%YOY) -51.21 9.84 1.09 -13.46 19.07
Net Margin (%) -332.94 -246.85 -167.26 -222.17 -102.21
EPS -0.2 -0.18 -0.13 -0.22 -0.13
Return on Equity (%) -21.42 -17.94 -13.15 -20.66 -12.39
Return on Assets (%) -19.7 -16.61 -12.17 -19.12 -11.45

Access our Ratings and Scores for Evogene Ltd.

Market Share Versus Profits

Revenues History
Earnings History

EVGN-US‘s change in revenue this period compared to the same period last year of -53.58% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that EVGN-US is holding onto its market share. Also, for comparison purposes, revenues changed by -15.04% and earnings by -14.59% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Earnings Growth Analysis

The company’s year-on-year decline in earnings was influenced by a weakening in gross margins from 24.84% to 7.68%, as well as issues with cost controls. As a result, operating margins (EBITDA margins) went from -96.68% to -298.50% in this time frame. For comparison, gross margins were 12.89% and EBITDA margins were -254.20% in the previous period.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

EVGN-US‘s decline in gross margins has not produced any significant offsetting improvement in its working capital . This leads Capital Cube to conclude that the decline in gross margins are likely from operating issues and not trade-offs with the balance sheet. Working capital days are currently 5,405.76 days, compared to last year’s level of 2,887.40 days.

Gross Margin Versus Working Capital Days

Quadrant label definitions. Hover to know more

Customer Financed, Cash Starved, Supplier Financed, Cash Rich

Cash Versus Earnings – Sustainable Performance?

EVGN-US‘s change in operating cash flow of -20% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings


The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -114.29% to -336.72% and (2) one-time items that contributed to a decrease in pretax margins from -102.21% to -331.58%

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Evogene Ltd.

Company Profile

Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of EVGN-US.